ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese. 2012

Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
Division of Occupational and Environmental Medicine, Lund University, SE-22185 Lund, Sweden.

BACKGROUND A higher prevalence of individuals affected by Parkinsonism was found in Valcamonica, Italy. This may be related to ferro-alloy smelters in the area, releasing manganese (Mn) in the air, soil and water for about a century. There exists individual susceptibility for Mn neurotoxicity. OBJECTIVE To analyse how polymorphism in genes regulating Mn metabolism and toxicity can modify neurophysiological effects of Mn exposure. METHODS Elderly (N=255) and adolescents (N=311) from Northern Italy were examined for neuromotor and olfactory functions. Exposure to Mn was assessed in blood and urine by atomic absorption spectroscopy and in soil by a portable instrument based on X-Ray fluorescence technology. Polymorphisms in the Parkinson-related gene ATPase type 13A2 (ATP13A2, also called PARK9: rs3738815, rs2076602, rs4920608, rs2871776 and rs2076600), and in the secretory pathway Ca(2+)/Mn(2+) ATPase isoform 1 gene (SPCA1: rs218498, rs3773814 and rs2669858) were analysed by TaqMan probes. RESULTS For both adolescents and elderly, negative correlations between Mn in soil and motor coordination (R(s)=-0.20, p<0.001; R(s)=-0.13, p=0.05, respectively) were demonstrated. Also among adolescents, negative correlations were seen between Mn in soil with odor identification (R(s)=-0.17, p<0.01). No associations were seen for Mn in blood or urine. ATP13A2 polymorphisms rs4920608 and rs2871776 significantly modified the effects of Mn exposure on impaired motor coordination in elderly (p for interaction=0.029, p=0.041, respectively), also after adjustments for age and gender. The rs2871776 altered a binding site for transcription factor insulinoma-associated 1. CONCLUSIONS ATP13A2 variation may be a risk marker for neurotoxic effects of Mn in humans.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D008297 Male Males
D008345 Manganese A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035)
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D012111 Residence Characteristics Elements of residence that characterize a population. They are applicable in determining need for and utilization of health services. Community,Domicile,Living Arrangements,Neighborhood,Place of Birth,Residential Selection,Arrangement, Living,Birth Place,Communities,Domiciles,Living Arrangement,Neighborhoods,Residence Characteristic

Related Publications

Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
January 2015, Cell cycle (Georgetown, Tex.),
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
January 2023, Frontiers in neurology,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
July 2012, Journal of neurochemistry,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
June 2012, Autophagy,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
November 2010, Movement disorders : official journal of the Movement Disorder Society,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
August 2019, Parkinsonism & related disorders,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
November 2021, Molecular cell,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
November 2014, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
June 2010, Movement disorders : official journal of the Movement Disorder Society,
Gerda Rentschler, and Loredana Covolo, and Amelia Ahmadi Haddad, and Roberto G Lucchini, and Silvia Zoni, and Karin Broberg
November 2021, The journal of physical chemistry. B,
Copied contents to your clipboard!